Lead Product(s): Momelotinib
Therapeutic Area: Oncology Product Name: GS-0387
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 11, 2021
Data highlights improved transfusion independence of momelotinib irrespective of baseline degree of anemia, platelet count or transfusion status. Efficacy data examining the association between transfusion independence and overall survival for momelotinib.
Lead Product(s): Lutetium–177 Octreotate
Therapeutic Area: Oncology Product Name: Lu-DOTATATE
Highest Development Status: Phase III Product Type: Peptide
Partner/Sponsor/Collaborator: Point Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 12, 2021
POINT Biopharma has signed a licensing and commercialization agreement with CanProbe for exclusive rights to Lutetium–177 Octreotate for the treatment of neuroendocrine cancer. Lu-DOTATATE as it is being used in 167 neuroendocrine tumor patients in a 180-patient trial.